Area of research
Cancer Research · Pathology and Forensic Medicine
Research interest
Research interests include Cancer Mechanisms and Therapy, Cancer, Hypoxia, and Metabolism, Microtubule and mitosis dynamics, and Cancer, Lipids, and Metabolism.
ACAT1‐Mediated ME2 Acetylation Drives Chemoresistance in Ovarian Cancer by Linking Glutaminolysis to Lactate Production
Galectin-3 suppresses CD8+ T cells function via myeloid-derived suppressor cells recruitment in cervical cancer
Fatty Acid Oxidation Supports Lymph Node Metastasis of Cervical Cancer via Acetyl‐CoA‐Mediated Stemness
Tyrosine catabolism enhances genotoxic chemotherapy by suppressing translesion DNA synthesis in epithelial ovarian cancer
Succinyl-CoA ligase ADP-forming subunit beta promotes stress granule assembly to regulate redox and drive cancer metastasis
ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer
EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer
Moonlighting functions of metabolic enzymes and metabolites in cancer
MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma
Circular RNA hsa_circ_0043280 inhibits cervical cancer tumor growth and metastasis via miR-203a-3p/PAQR3 axis
Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1
Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis
Mutant p53 in Cancer Progression and Targeted Therapies
DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN–WEE1 Signaling
Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation
Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation
The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer